Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors :: Desta Z
Gammal RS
Gong L
Whirl-Carrillo M
Gaur AH
Sukasem C
Hockings J
Myers A
Swart M
Tyndale RF
Masimirembwa C
Iwuchukwu OF
Chirwa S
Lennox J
Gaedigk A
Klein TE
Haas DW
Source :: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Oct; Vol. 106 (4), pp. 726-733. Date of Electronic Publication: 2019 Jul 05.
Publication Year :: 2019
Abstract: The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.<br /> (© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.)

Subjects :: Alkynes
Anti-HIV Agents pharmacology
Cyclopropanes
Humans
Pharmacogenetics
Practice Guidelines as Topic
Benzoxazines pharmacology
Cytochrome P-450 CYP2B6 genetics
HIV Infections drug therapy
HIV Infections genetics
HIV-1
Pharmacogenomic Testing methods

Full Text Access

Tools